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Abstract
Background: Duchenne muscular dystrophy, a fatal muscle-wasting disease, is characterized by dystrophin
deficiency caused by mutations in the dystrophin gene. Skipping of a target dystrophin exon during splicing with
antisense oligonucleotides is attracting much attention as the most plausible way to express dystrophin in DMD.
Antisense oligonucleotides have been designed against splicing regulatory sequences such as splicing enhancer
sequences of target exons. Recently, we reported that a chemical kinase inhibitor specifically enhances the
skipping of mutated dystrophin exon 31, indicating the existence of exon-specific splicing regulatory systems.
However, the basis for such individual regulatory systems is largely unknown. Here, we categorized the dystrophin
exons in terms of their splicing regulatory factors.
Results: Using a computer-based machine learning system, we first constructed a decision tree separating 77
authentic from 14 known cryptic exons using 25 indexes of splicing regulatory factors as decision markers. We
evaluated the classification accuracy of a novel cryptic exon (exon 11a) identified in this study. However, the tree
mislabeled exon 11a as a true exon. Therefore, we re-constructed the decision tree to separate all 15 cryptic exons.
The revised decision tree categorized the 77 authentic exons into five groups. Furthermore, all nine disease-
associated novel exons were successfully categorized as exons, validating the decision tree. One group, consisting
of 30 exons, was characterized by a high density of exonic splicing enhancer sequences. This suggests that AOs
targeting splicing enhancer sequences would efficiently induce skipping of exons belonging to this group.
Conclusions: The decision tree categorized the 77 authentic exons into five groups. Our classification may help to
establish the strategy for exon skipping therapy for Duchenne muscular dystrophy.
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Background
Duchenne muscular dystrophy (DMD), a fatal muscle-
wasting disease, is the most common inherited muscle dis-
ease, affecting one in every 3500 male births. DMD is
characterized by dystrophin deficiency caused by muta-
tions in the dystrophin gene, the largest human gene that
spans over 2500 kb on the X-chromosome. For the treat-
ment of DMD, antisense oligonucleotides (AOs) against
splicing regulatory sequences have been proposed to
produce in-frame dystrophin mRNA from the out-of-
frame mRNA by inducing exon skipping during splicing
[1]. The newly generated in-frame dystrophin mRNA is
expected to produce semi-functional, internally deleted
dystrophin protein. Currently, induction of exon skipping
with AOs is considered one of the most promising treat-
ments for DMD [2,3].
The dystrophin gene encodes a 14-kb mRNA consisting
of 79 exons and is characterized by its huge intron size;
the largest, intron 44, is 248 kb long. In addition, eight
alternative promoters that are activated in a tissue-specific
manner have been identified. Each tissue-specific exon 1
under the control of a cryptic promoter is spliced correctly
* Correspondence: mmatsuo@reha.kobegakuin.ac.jp
1Department of Pediatrics, Graduate School of Medicine, Kobe University,
Chuo, Kobe 6500017, Japan
Full list of author information is available at the end of the article
Malueka et al. BMC Genetics 2012, 13:23
http://www.biomedcentral.com/1471-2156/13/23
© 2012 Malueka et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.to one of the downstream authentic dystrophin exons, pro-
ducing a tissue-specific dystrophin isoform [4,5]. Further-
more, alternative splicings of some exons lead to the
production of additional isoforms of the tissue-specific
transcripts [6-8]. Remarkably, 14 cryptic exons that resem-
ble authentic exons in terms of length and splice site
strength, but are very rarely if ever spliced, have been
reported within the huge introns [9,10].
Splicing is the process that removes introns from pre-
mRNA, and is performed in the spliceosome, a ribonucleo-
protein assembly. The spliceosome is one of the most com-
plex cellular machineries, comprising approximately 150
proteins and five small nuclear RNAs (snRNAs U1, U2,
U4, U5, and U6) [11]. Three sites, the splice donor site
(5’ss), the splice acceptor site (3’ss), and the branch point
sequences are the core splice site signals that are present in
every intron. Despite the high potential for errors, the spli-
cing process appears to occur with high fidelity, implying
the widespread involvement of additional transcript fea-
tures. These exonic elements are conventionally classified
as exonic splicing enhancers (ESEs) or silencers (ESSs) and
they function to promote or inhibit inclusion of the exon
in which they reside, respectively. These splicing regulatory
elements function by recruiting trans-acting splicing fac-
tors that activate or suppress splice site recognition or spli-
ceosome assembly by various mechanisms [12]. AOs that
induce skipping of dystrophin exons have been mainly
designed against ESEs of target exons to hamper recruit-
ment of splicing factors [2,3].
Recently, we reported that a small chemical enhances
skipping of mutated dystrophin exon 31 in a sequence-
specific manner, not altering the splicing of other dystro-
phin exons [13]. It was strongly suggested that dystrophin
exons have their own splicing regulatory systems. How-
ever, the characteristics of the splicing regulatory systems
of individual dystrophin exons are not well understood.
Decision trees are classifiers that predict class labels for
data items and can make very accurate predictions [14,15].
They have been used to establish an integrated method
that is one of the best available ways to find genes in the
human genome [15].
Here, we identified a novel cryptic exon in intron 11 of
the dystrophin gene in a DMD patient, and constructed
decision trees to discriminate authentic exons from cryp-
tic exons. Finally, we categorized 77 authentic exons into
five groups based on indexes of their splicing regulatory
factors. From the decision tree, we suppose that one
group of exons showing high density for ESE sequences
are a good target for exon skipping therapy.
Results
To examine the splicing regulatory factors that character-
ize particular exons, we constructed decision trees classi-
fying authentic from cryptic exons using indexes of
splicing regulatory factors as decision markers. Cryptic
exons within the dystrophin gene resemble authentic
exons in terms of length and splice site strength, but are
very rarely if ever spliced [10]. Therefore, analyzing the
exon recognition parameters of these exons compared to
the authentic dystrophin exons can give insight into
which splicing regulatory elements actually play a critical
role in the splicing of dystrophin exons. The goal of the
decision tree was to determine the critical parameters
that provided the most accurate categorization of authen-
tic exons and cryptic exons. A preliminary decision tree
was constructed to discriminate 77 authentic exons from
14 known cryptic exons. To classify these exons, we used
26 indexes that have been reported as important in
proper splicing (see Methods). The decision tree system
output a simple data structure (Figure 1). The decision
tree revealed that the strength of the 3’ss calculated by
maximum entropy (ME3’ss) was the first splitting vari-
able, with a cut-off point of 1.39. At this node, four cryp-
tic exons were classified into one group. At the next
node, SF2/ASF-D was used as the splitting variable, with
a cut-off point of less than 10.44, generating a group of
32 authentic exons. In this way, seven nodes were used
to separate clearly the 77 authentic exons from the 14
cryptic exons. The authentic exons were categorized into
four groups, comprising 43, 32, 1, and 1 exon, respec-
tively; similarly, the cryptic exons were also categorized
into four groups.
We evaluated the decision tree by analyzing a novel
cryptic exon 11a that was identified in this study. Exon
11a was found inserted into dystrophin mRNA in one
DMD case who had a two-nucleotide (CA) deletion at the
5th and 6th nucleotides of exon 12 (c.1336_1337del). RT-
nested PCR amplification of a fragment spanning exons 10
to 14 from this individual revealed two products: one cor-
responding to the normal size and the other larger than
expected (Figure 2). Sequencing of the two products
revealed that the normal-size band had the predicted exon
content with the two-nucleotide deletion, and the larger
product contained a 157-bp unknown insertion between
exons 11 and 12. The inserted 157-bp sequence was iden-
tical to part of the 29.7-kb-long intron 11. The corre-
sponding intronic sequence was present 5244 nt
downstream of the 3’ end of exon 11 and 24,278 nt
upstream of exon 12 (Figure 2c). The inserted sequence
maintained the AG and GT dinucleotide consensus
sequences for splicing acceptor and donor sites at either
end. Although the sequences flanking the inserted
sequence were examined in this individual, no nucleotide
change was found. The inserted sequence was named
exon 11a.
When we tested exon 11a on our decision tree, it was
classified not as a cryptic exon but as a real exon. There-
fore, we decided that this tree was not suitable to classify
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Page 2 of 10exon 11a. We reconstructed the decision tree, including
exon 11a as an additional cryptic exon using the same 26
indexes that were used to construct the first decision
tree. The final tree, which had eight nodes, was able to
separate all 15 cryptic exons from all 77 authentic exons
with 100% accuracy (Figure 3). ME3’ss was the first split-
ting variable, with a cut-off point of 1.39. At this node,
four cryptic exons were classified into one group (group
a; Figure 3). SF2/ASF-D was the splitting variable at the
second node, with a cut-off point of 10.53. A group of
32 exons (group A) was categorized on its “no” branch.
Group A, therefore, was characterized by a high-density
of ESEs recognized by SF2/ASF. At the third node,
ME5’ss with a cut-off point of 5.58 was used to divide the
data into two subnodes. On the “yes” branch, FE with a
cut-off point of -2.6 split the group: one exon group con-
sisting of five cryptic exons (group b) and one exon
group containing only exon 27 (group B). On the other,
“no” branch, FESS-D with a cut-off point of 4.45 divided
the group into two subnodes. On the “yes” branch,
GC5’ss with a cut-off point of 46.8 was used at the fifth
node. One big exon group (group C), comprising 42
exons, formed the “yes” branch. On the other, “no”
branch, SH3’ss with a cut-off point of 0.79 was used at
the sixth node, generating a cryptic exon group (group c)
and a group containing two authentic exons (exons 70
Figure 1 Preliminary decision tree to classify 77 authentic and 14 cryptic dystrophin exons. Exons are passed down the tree beginning at
the top, where a “yes” result on any test means that it should be passed down to the left. The features tested in this tree are the maximum
entropy at the 3’ splice site (ss) (ME3’ss), the SF2/ASF density (SF2/ASF-D), the GC content at the 5’ss (GC5’ss), the maximum entropy at the 5’ss
(ME5’ss), the free energy at the 5’ss U1 snRNP binding site (FE), the number of exonic splicing silencer (FESS), and the Shapiro score at the 3’ss
(SH3’ss). The internal nodes of the tree represent index values that are tested for each exon as it is passed through the tree. Each successive
node in the tree represents a decision that is based on those values, until a final classification is reached (the leaves). Authentic and cryptic
exons were classified into four groups each.
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Page 3 of 10and 78; group E). On the “no” branch at the fourth node,
SIZE with a cut-off point of 144 was next used, categoriz-
ing the final data into one exon group consisting of exons
2 and 3 (group D) and one group containing four cryptic
exons (group d).
We evaluated our re-constructed tree using nine dis-
ease-causing exons that have been identified in the dys-
trophin mRNAs of dystrophinopathy patients. These
pathological exons are created by the effect of deep-
intron single nucleotide mutations. These mutations
confer the characteristics of an authentic exon on a por-
tion of intronic sequence, and thus the intron segment
becomes recognized as an exon during the splicing pro-
cess. Therefore, the decision tree should categorize
these pathological exons as authentic exons. Remark-
ably, all nine pathological exons were correctly categor-
ized into one of the four exon groups: four in group A,
three in group C, and one in each of groups D and E.
Therefore, we consider our decision tree a suitable clas-
sifier of pathological dystrophin exons.
Seven indexes were used in common by both the preli-
minary and re-constructed trees. However, their values in
each tree were different, except for one (≤ 1.39 ME3’ss
score at the first node). When we compared the two trees,
we found that three exons (2, 70, and 78) and two exons
(40 and 56) were re-categorized into small groups (groups
E and D) and the largest group (group C), respectively.
This indicated slight changes in the categorizing pathways
between the two trees. The cryptic exons were ultimately
categorized into four groups, and exon 11a belonged to
group d, which comprises exons 1a, 2a, and 3a-l. It was
interesting that group D was categorized by a SIZE score
of ≤ 114 (Figure 3). This indicates that a small exon can be
real if the splicing silencer density is high.
A m o n gt h e2 6i n d e x e su s e da sc andidates for the decision
markers, only eight were used in the tree. Furthermore, five
Figure 2 Cloning of cryptic exon 11a. a. RT-nested PCR products. A fragment spanning exons 10 to 14 was amplified by RT-nested PCR. Two
amplified products were obtained from peripheral lymphocytes of a DMD patient (P) but not a control (C). A schematic representation of the
exon structure of the amplified fragments is shown on the right. b. Sequences at the exon junctions. Subcloning and sequencing of the
amplified products revealed that the larger product contained a 157-bp insertion (exon 11a) between exons 11 and 12. c. Schematic description
of the location of exon 11a. The 5’ and 3’ ends of exon 11a (hatched box) are 5.2 kb downstream of exon 11, and 24.3 kb upstream of exon 12,
respectively. Both the AG and GT splicing consensus dinucleotides are present adjacent to exon 11a.
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sites (Table 1). This indicates that recognition of the spli-
cing sites is very important for proper splicing. Group E
(exons 70 and 78) was categorized through six nodes; the
final one discriminating it from group c (cryptic exons 2b
and 77a). For this categorization, the strength of the 3’ss
was tested twice using different indexes (ME3’ss and
SH3’ss). This indicates the importance of the 3’ss strength
relative to the 5’ss strength in dystrophin splicing. Indexes
of ESE density (SF2/ASF-D) and ESS density (FESS-D)
were also used in the tree. This indicates that both the ESE
and ESS densities are important in the splicing process.
Next, we used the tree to characterize exons that are
subjected to specific splicing patterns. First, we marked
exons known to be alternatively spliced (data not shown).
However, they were found in all five groups. This indicates
that no particular cis-elements predispose to alternative
splicing. Second, we examined exons that were prone to
splicing errors caused by intra-exon mutation. We have
previously reported nonsense mutation-induced exon
skipping in seven exons (exons 14, 15, 17, 27, 41, 42, and
70) [16]. Among these, only four (exons 17, 27, 41, and
42) cause disruption of an ESE. Remarkably, exons 17, 41,
and 42 were categorized in group A, while all those that
do not disrupt an ESE were categorized in other groups.
This indicates that, for exons in group A, nonsense muta-
tion-induced exon skipping is caused by disruption of an
ESE, while for exons in other groups, nonsense mutation-
induced exon skipping is caused by other factors. Third,
we examined exons that splice to tissue-specific exon 1
(exons 2, 30, 45, 56, and 63). We did not identify any par-
ticular categorization characteristics for these exons.
Discussion
The dystrophin gene produces many mRNAs because it
is so complex: it contains 79 exons, huge introns, eight
Figure 3 Final decision tree to classify 77 authentic and 15 cryptic dystrophin exons. The structure of the tree is as described for Figure 1.
The features tested in this tree include seven indexes used in the preliminary tree (Figure 1) and one additional index, exon size (SIZE). This tree
classified the authentic dystrophin exons into five groups (groups A to E), containing 30, 1, 42, 2, and 2 exons, respectively. The cryptic exons
were classified into four groups (groups a to d).
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ates many alternatively spliced products. It has been
reported that there is a gradient in exon and intron defi-
nition at the level of pre-mRNA splicing [17]. For exam-
ple, efficient use of intrinsically weak cryptic splice sites
in exons is facilitated by a higher-than-average density
of ESSs and a high density of SF2/ASF ESE motifs [17].
This suggests that each exon has a specific splicing reg-
ulatory mechanism in which particular splicing factors
could compensate for the lack of other splicing factors.
It is important to understand more about the splicing
regulatory mechanisms for each exon of the dystrophin
gene because treatment with exon skipping is a promis-
ing therapeutic approach.
Decision trees have been used in many kinds of classifi-
cations, such as for the management of Parkinson’sd i s -
ease, disease severity profiling, large-scale proteomic
studies, and microarray data classification [14,18]. Here,
we classified 77 authentic and 15 cryptic dystrophin exons
into five groups based on their splicing regulatory factor
characteristics. In this study, we needed to modify our pre-
liminary decision tree (Figure 1) based on data from the
novel exon 11a (Figure 2). This suggested a possibility that
the tree needs further modification when another cryptic
exon is identified in the future construction. However, we
believe any modifications, if necessary, will be minimal as
exon 11a was additionally analyzed (Figure 3). Moreover,
our trees were constructed using indexes obtained only
from cis-elements; further modification incorporating
information from trans-elements may further improve the
reliability of the tree.
We used our decision tree to determine the parameters
that are most useful for the discrimination of authentic
and cryptic dystrophin exons. We separated the two cate-
gories completely using eight variables: (1) strength of the
3’ss measured by maximum entropy score; (2) density of
ESEs particularly SF2/ASF; (3) strength of the 5’ss mea-
sured by maximum entropy score; (4) free energy in U1-
snRNP binding to the 5’ss; (5) density of ESSs as identified
by FESS-D; (6) GC content at the 5’ss; (7) exon size; and
(8) strength of the 3’ss as measured by the Shapiro score.
In other words, the strength of the 3’ss consensus
sequence as indicated by maximum entropy score is the
most critical, as all authentic dystrophin exons must have
a maximum entropy score of more than 1.39 at the 3’ss.
The next most important deciding factor is ESE density,
particularly for SF2/ASF; almost half (30) of dystrophin
exons can be classified based on this parameter and 3’ss
strength only. These findings are in line with those of a
previous report, which showed that exons that are skipped
because of splice site mutations have a weaker 3’ss and a
lower-than-average density of ESEs [17].
Our exon categorization suggested that there are at least
five different patterns of splicing regulatory mechanisms
for dystrophin pre-mRNAs (Table 1). At the extreme, one
group contained only one exon (exon 27; group B), imply-
ing that this exon has a unique splicing regulatory
mechanism. In fact, alteration of exon 27 splicing has been
reported for two nonsense mutations, resulting in a mild
phenotype [19]. Exon 27 may be particularly vulnerable to
splicing alterations caused by intra-exonic mutations.
On the other hand, two groups (A and C) contained 72
out of 77 exons, suggesting that most dystrophin exons are
under similar splicing control. Group A, consisting of 32
exons, was characterized by a high density of ESEs, particu-
larly SF2/ASF (more than 10.53) (Figure 3) (Table 1), indi-
cating that ESE density plays a critical role in the splicing
of these exons. Disruption of ESEs for exons in this group
is more likely to cause exon skipping compared with dis-
ruption of ESEs in the other exon groups. Nonsense muta-
tions within exons 17, 41, and 42, all belonging to group A,
have been shown to induce exon skipping [16]. Accord-
ingly, the nonsense mutations in these three exons disrupt
an ESE sequence and thus cause exon skipping, while non-
sense mutations that induce skipping of exons in other
groups do not disrupt an ESE [16]. However, not all ESE-
disrupting nonsense mutations identified in these exons
induce exon skipping [16]. It may be necessary to consider
trans-elements to explain these differences, along with the
strength of splicing factor binding to the ESEs and their
positions in the pre-mRNA secondary structure.
Intronic pseudo-exons that look like perfect exons,
maintaining splicing consensus sequences, are now
under intensive investigation [10,20-22]. There is
Table 1 Summary of categorization of exons by the decision tree
Number of Exon Indexes
ME3’ss SF2/ASF-D ME5’SS FE FESS-D GC5’ss SH3’ss SIZE
Group A 30 HH --- - - -
B 1 HLL H --- -
C 42 HLH - LL--
D 2 HLH - H -- L
E 2 HLH - LH H -
Results of categorization of 77 dystrophin exons are tabulated. Indexes determining the strength of splice sites are marked bold. H and L represent high and low
at each node, respectively. Bars indicate not applicable.
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mRNAs is actively inhibited because of the presence of
intrinsic defects, the presence of silencer elements, or
the formation of an inhibitory RNA secondary structure
[23]. We categorized the cryptic exons into four groups
(Figure 3), indicating a heterogeneous contribution of
splicing factors required for their activation.
Group C contained 42 exons and was separated at the
fifth node by a score of less than 46.8% GC content at the
5’ss. More than half of the dystrophin exons belonged to
this group and are therefore presumed to be subject to
similar splicing regulation. From the decision tree we can
see that this group is characterized also by an ESS density
≤ 4.45 (FESS-D), indicating that splicing silencer signals
play a critical role in the splicing of these exons. Indeed,
we showed previously that nonsense mutation-induced
exon skipping of exon 31 was caused by the creation of a
splicing silencer-binding site for hnRNP A1 [13]. It has
been reported that negative elements play important roles
in distinguishing real splicing signals from the vast num-
ber of false-positive splicing signals [9].
Because the dystrophin gene is so complex, it has the
potential to produce many alternatively spliced transcripts
that are translated into protein variants [24]. However,
studies on alternative splicing are limited [6-8]. In one
study, Sironi et al. identified 16 alternative transcripts and
examined splicing regulatory factors such as the 3’ and 5’
consensus values and exonic splicing enhancer scoring
matrices; however, no reasonable explanation of the alter-
n a t i v es p l i c i n gw a si d e n t i f i e d[ 7 ] .T h i si sc o n s i s t e n tw i t h
our findings that the cryptic exons fell into five different
groups. It is possible that alternative splicing does not rely
completely on specific sequence elements and is regulated
by trans-acting factors.
Interest in the splicing regulation of dystrophin pre-
mRNA was first aroused when exon skipping caused by
a small intra-exonic deletion was identified in a DMD
patient [25]. Subsequently it was revealed that the
deleted region was an ESE sequence within exon 19 [1]
and that AOs against this ESE successfully induced the
skipping of exon 19 [26]. This has led to the establish-
ment of exon-skipping therapy [27]. In this study, we
demonstrated that exon 19 was categorized into group
A, characterized by a high ESE density; hence it is rea-
sonable that AOs against the exon 19 ESE would induce
exon skipping efficiently. Currently exon skipping is
recognized as the most promising way to express dystro-
phin in DMD. The main targets for exon skipping ther-
apy are exons 44, 45, 51, and 53 [28] and AOs against
exon 51 are now in phase II or III clinical trials [2,3].
Because exons 45, 51, and 53 belong to group A, we
would expect AOs against the ESEs in these exons to
work well.
Conclusions
The decision tree categorized the 77 authentic dystrophin
exons into five groups. Our classification may help to
establish the strategy for exon skipping therapy for DMD.
Methods
Indexes of splicing regulatory factors
The sequences of 14 known cryptic exons, and nine dis-
ease-causing mutations were obtained from our previous
report [10] and the literature [29,30]. Twenty six indexes
of splicing regulatory factors of each exon were obtained
as described below (Table 2).
Splice site strength
Splice site strength was determined in three ways: Sha-
piro’s splicing probability matrix scores at the 5’ss and the
3’ss were calculated using published formulae [17,31]
(SH5’ss and SH3’ss, respectively). Maximum entropy
scores at the 5’ss and the 3’ss were obtained using online
tools available at http://genes.mit.edu/burgelab/maxent/
Xmaxentscan_scoreseq.html (ME5’ss and ME3’ss, respec-
tively) [32]. Information content values at the 5’ss and the
3’ss were obtained using the Delila server at https://splice.
uwo.ca/ (Ri5’ss and Ri3’ss, respectively) [33].
Free energy of U1 snRNA binding to the 5’ss
U1 snRNA binding to constitutive splice sites has lower
free energy than that of its binding to alternatively spliced
exon splice sites [34]. Free energy was analyzed using the
SROOGLE server at http://sroogle.tau.ac.il/ (FE) [35].
Numbers and densities of ESEs and ESSs
The number of ESEs in each exon was calculated using
the prediction algorithm at http://genes.mit.edu/burge-
lab/rescue-ese/ (RESE). The number of ESSs was calcu-
lated using two algorithms: at http://genes.mit.edu/
fas-ess/ (FESS) and http://cubweb.biology.columbia.
edu/pesx/ (PESS) [17,36-38]. To calculate the densities
of ESSs/ESEs, the RESE, FESS, and PESS numbers
were divided by the sequence length (in nucleotides)
and this figure was multiplied by 100 [17] to give the
RESE-D, FESS-D, and PESS-D scores.
The numbers of binding sites for the four SR proteins
(SF2/ASF, SRp40, SC35, and SRp55) were obtained using
ESEfinder (v. 3.0) available at http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home (SF2/ASF-N,
SRp40-N, SC35-N, and SRp55-N) [39]. The density of SR
protein-binding sites (SF2/ASF-D, SC35-D, SRp40-D,
SRp55-D) was obtained by dividing each number by its
nucleotide length then multiplying it by 100 [17].
Minimum free energy value of pre-mRNA secondary
structure and GC content around splice sites
Minimum free energy values of the pre-mRNA second-
ary structure at the 5’ss and 3’ss were obtained using
the free energy minimization program RNAfold http://
rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi using the 70
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site (RSS5’ss and RSS3’ss, respectively) [40,41].
GC content around splice sites has been reported to
affect splicing [40]. Thus, the percentage of GC content
for each 70 nucleotides both up- and down-stream of
the 5’ss and the 3’ss was calculated (GC5’ss and GC3’ss,
respectively) [40].
Exon size
The number of nucleotides in each exon was also taken
into account (SIZE).
Construction of decision trees
The C4.5 algorithm was used to construct decision
trees. The C4.5 decision tree algorithm is an approach
for pattern recognition and data mining [42,43] and was
developed by Quinlan [44,45]. The algorithm uses infor-
mation gain, which is an entropy-based criterion in
information theory for decision tree construction. In
this study, the conditions were as follows: (1) at least
one object was to be contained in each branch, (2) the
pruning confidence level was set to 100%, and (3) the
iterative mode was used to avoid a local optimum.
We used 92 out of 94 data points (79 exons and 15
cryptic exons) for decision tree construction. We
excluded two exons, exons 1 and 79, because they lacked
some feature values.
Dystrophin mRNA analysis
A 1-year-old Japanese boy (KUCG 952) without any family
history of neuromuscular disorders was referred to Kobe
University Hospital (Kobe, Japan) because of a high serum
creatine kinase level (37,110 IU/l). DMD was tentatively
diagnosed, and mutation in the dystrophin gene was ana-
lyzed after obtaining informed consent from his parents.
Dystrophin mRNA expressed in his peripheral lympho-
cytes was analyzed as described previously [10,25]. A frag-
ment spanning exons 10 to 14 was amplified by reverse
transcription (RT)-nested PCR using two sets of primers.
The outer primer set comprised a forward primer, 1A 5’-
TTTTTATCGCTGCCTTGATATACA-3’ and a reverse
primer, 1B 5’-ACTCTGCAACACAGCTTCTGAG-3’; the
inner primer set comprised a forward primer, 1E 5’-
TTGCAAGCACAAGGAGAGATT-3’ and a reverse pri-
mer, c14r 5’-ACGTTGCCATTTGAGAAGGAT-3’.T h e
Table 2 Indexes of splicing regulatory factors
No Features Symbol Reference
15 ’ splice site strength (Shapiro score) SH5’ss [31]
23 ’ splice site strength (Shapiro score) SH3’ss [31]
35 ’ spice site strength (maximum entropy) ME5’ss [32]
43 ’ spice site strength (maximum entropy) ME3’ss [32]
55 ’ splice site strength (information content/Ri) Ri5’ss [33]
63 ’ splice site strength (information content/Ri) Ri3’ss [33]
7 U1 SnRNA binding free energy FE [35]
8 ESE density (RESCUE ESE/RESE) RESE-D [36]
9 ESE density (PESE) PESE-D [38]
10 ESS density (FAS-ESS/FESS) FESS-D [37]
11 ESS density (PESS) PESS-D [38]
12 SF2/ASF number SF2/ASF-N [39]
13 SF2/ASF (IgM/BRCA1) number SF2/ASF (IgM, BRCA1)-N [39]
14 SRp40 number SRp40-N [39]
15 SC35 number SC35-N [39]
16 SRp55 number SRp55-N [39]
17 SF2/ASF score density SF2/ASF-D [39]
18 SF2/ASF (IgM/BRCA1) score density SF2/ASF (IgM-BRCA1)-D [39]
19 SC35 score density SC35-D [39]
20 SRp40 score density SRp40-D [39]
21 SRp55 score density SRp55-D [39]
22 5’ splice site pre-mRNA secondary structure free energy RSS5’ss [40]
23 3’ splice site pre-mRNA secondary structure free energy RSS3’ss [40]
24 5’ splice site GC content GC5’ss [40]
25 3’ splice site GC content GC3’ss [40]
26 The number of nucleotides in exon SIZE
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Page 8 of 10amplified fragments were resolved by agarose gel electro-
phoresis. Sequencing of the amplified products was per-
formed by subcloning sequencing as described previously
[46].
The mutation study was approved by our ethical com-
mittee and mutation analysis of the dystrophin gene was
done after obtaining the informed consent from the par-
ents of the patient.
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